OpinionSMMT
Summit Therapeutics is getting punished like a broken biotech when the real issue is financing
Summit Therapeutics is trading like ivonescimab broke, but the key catalyst is still on the calendar. The market is hammering SMMT for financing and credibility risk, and that distinction matters because those are fixable problems while the November 2026 FDA decision remains alive.
Jun 2, 20264 MIN